Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number Sort descending | Lead Group | Study Title | CIRB | Study Status | |
|---|---|---|---|---|---|
| S2206 | SWOG | Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2207 | SWOG | Randomized Phase II Study of the Addition of Targeted Therapeutic Agents to Tafasitamab-Based Therapy in Non-Transplant-Eligible Patients with Relapsed/Refractory Large B-Cell Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2209 | SWOG | A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or in a Subset of “Intermediate Fit” Comparing Upfront Three-Drug Induction Regimens Followed by Double- or Single-Agent Maintenance | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2210 | SWOG | A Phase II Study of Neoadjuvant Carboplatin for Localized, High Risk Prostate Cancer with Germline BRCA1/2 Mutations | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2212 | SWOG | Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2213 | SWOG | A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2302 | SWOG | Pragmatica - Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) plus Pembrolizumab (MK-3475; NSC 776864) versus Standard of Care (SOC) for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2303 | SWOG | Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2308 | SWOG | Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma | Adult CIRB - Late Phase Emphasis | Available to Open | |
| S2312 | SWOG | A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with Metastatic Castrate Resistant Prostate Cancer (MCRPC), Stratified by Aggressive Variant Signature | Adult CIRB - Late Phase Emphasis | Available to Open |